CN104693288A - Fibroblast growth factor inhibiting polypeptides and application thereof - Google Patents
Fibroblast growth factor inhibiting polypeptides and application thereof Download PDFInfo
- Publication number
- CN104693288A CN104693288A CN201510149467.7A CN201510149467A CN104693288A CN 104693288 A CN104693288 A CN 104693288A CN 201510149467 A CN201510149467 A CN 201510149467A CN 104693288 A CN104693288 A CN 104693288A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- fibroblast growth
- polypeptide
- suppresses
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
Abstract
The invention discloses a fibroblast growth factor inhibiting polypeptides and application thereof, and relates to the field of medicines, in particular to polypeptides with a fibroblast growth factor inhibiting function and used for treating a malignant tumor. The sequence is GMLGGQEMWSWKCLLFWLKRRNFWQG and is a bran-new sequence, the polypeptides can inhibit proliferation of colon cancer cells and hepatoma cells in vitro and increase the survival rate of tumor-bearing mice in in-vivo tests and has potential new drug development value.
Description
Technical field
The present invention relates to fibroblast growth factor and suppress polypeptide and application thereof, be specifically related to have and be suppressed to fibroblast growth factor, the polypeptide for the treatment of malignant tumour.
Background technology
Vasculogenesis is that after malignant entity tumor breaks through basement membrane of epithelium, further growth is necessary.In tumour, the new blood vessel formed has the constructional feature of himself uniqueness, shows as tube wall imperfect, without smooth muscle elements, is only made up of the basement membrane of porose endotheliocyte and sheet.Most scholar thinks, the constructional feature of new vessel makes malignant tumor tissue generation distant metastasis become possibility.Therefore, in malignant entity tumor new vessel be quantitatively considered to a kind of important independently prognostic marker.
Fibroblast growth factor, have tumour cell and significantly tend to active, stimulate inoblast, vascular endothelial cell etc. move to lesions position.When cell migration is to lesions position, start to enter propagation and reparation phase, wherein one of the step of most critical is the formation of granulation tissue, the essence of granulation tissue is a large amount of capillary vesseies and abundant inoblast, it is the efficient growth promoter of inoblast, vascular endothelial cell and vascular smooth muscle cell, strongly can promote the formation of new capillary vessel, remarkable increase granulation tissue capillary vessel quantity and blood flow, for tumor tissues provides required oxygen and abundant nutritive substance, promote the growth of tumour.Be suppressed to fibroblast growth factor, can the new life of effective Tumor suppression blood vessels in tissue, break off oxygen and the nutritive substance of tumor tissue growth's needs, tumour cell " is died of hunger ".Thus, reach the effect for the treatment of tumour.
At present, do not have the fibroblast growth factor of ripe exploitation to suppress polypeptide to come out, be used for the treatment of malignant tumour.
It is effective that fibroblast growth factor in this patent suppresses polypeptide to prove in colon carninomatosis, has the prospect developed in other tumor models.
Summary of the invention
Goal of the invention
The invention provides brand-new sequence, this sequence is fibroblast growth factor antagonist, has good curative effect to malignant tumour.
Technical scheme
Fibroblast growth factor suppresses polypeptide, it is characterized in that its sequence is GMLGGQEMWSWKCLLFWLKRRNFWQG.
Described fibroblast growth factor suppresses the application of polypeptide in preparation tumor.
Described fibroblast growth factor suppresses polypeptide preparing the application in Hepatoma therapy medicine.
Detect a test kit for tumour, it contains fibroblast growth factor according to claim 1 and suppresses polypeptide.
Described test kit, is characterized in that also having
(1) the 0.05mol/L carbonate buffer solution of coating buffer: pH9.6;
(2) the 0.02mol/L phosphate buffered saline buffer of PBS damping fluid: pH7.4;
(3) 0.02mol/LPBS and 0.2%BSA of antibody diluent: pH7.4;
(4) the 0.05mol/L carbonate buffer solution of confining liquid: pH9.6 and 2.0%BSA
(5) washings: 0.02mol/LPBS (pH7.4) and 0.05%Tween-20;
(6) substrate solution: solubility single-component tmb substrate solution;
(7) stop buffer: 2mol/L sulphuric acid soln;
(8) fibroblast growth factor antibody;
(9) goat anti-mouse IgG.
Beneficial effect
Utilize solid-phase synthesis chemosynthesis fibroblast growth factor to suppress polypeptide, this polypeptide has brand-new sequence, and this polypeptide can vitro inhibition fibroblast growth factor, and treatment malignant tumour, as colorectal carcinoma.The fibroblast growth factor that we find suppresses polypeptide can suppress Colon Cancer Cells vigor simultaneously, and improves tumor-bearing mice survival rate in testing in vivo, has potential new drug development value.
Embodiment
Fibroblast growth factor suppresses polypeptide to be synthesized by the biochemical (Shanghai) Co., Ltd. of gill.
Embodiment 1
Fibroblast growth factor suppresses polypeptide to the growth of vitro culture human colon cancer cell and survival IC50.
Adopt MTT colorimetry.By the human colon cancer cell of logarithmic growth, add in 96 well culture plates with 1.0 × 105, cultivate 24h, the Experimental agents fibroblast growth factor that experimental port, positive drug control hole add different concns respectively suppresses polypeptide (the raw work synthesis in Shanghai) and positive control medicine taxol; Blank group adds the solvent of same volume.Five multiple holes are established in every hole, cultivate 48h, respectively 0h, 2h, 8h, 14h, 20h, 24h, 36h, the every hole of 48h adds MTT, after effect 4h, add DMSO, hatch 30min, absorbance A value is measured, by formula human colon cancer cell growth inhibition ratio=(1-experimental group light absorption value/control group light absorption value) × 100% at microplate reader 620nm place.The IC50 calculating Experimental agents is 5.8 μMs, and the IC50 of positive control drug is 4.2 μMs.
Embodiment 2
Fibroblast growth factor suppresses polypeptide to the growth of Human Hepatocarcinoma Cell line in vitro and survival IC50.
Adopt MTT colorimetry.By the human hepatoma HepG2 cell of logarithmic growth, add in 96 well culture plates with 1.0 × 105, cultivate 24h, the Experimental agents fibroblast growth factor that experimental port, positive drug control hole add different concns respectively suppresses polypeptide (the raw work synthesis in Shanghai) and positive control medicine taxol; Blank group adds the solvent of same volume.Five multiple holes are established in every hole, cultivate 48h, respectively 0h, 2h, 8h, 14h, 20h, 24h, 36h, the every hole of 48h adds MTT, after effect 4h, add DMSO, hatch 30min, absorbance A value is measured, by formula human HepG2 cell growth inhibition ratio=(1-experimental group light absorption value/control group light absorption value) × 100% at microplate reader 620nm place.The IC50 calculating Experimental agents is 7.9 μMs, and the IC50 of positive control drug is 4.9 μMs.
Embodiment 3
With tumor model be detected as fibroblast growth factor suppress polypeptide body in vigor.
Set up colon carcinoma tumor model, positive control medicine taxol 5mg/Kg; 0.75,1.5,3mg/Kg blank group adds the solvent of same volume, and experimental group polypeptide establishes 3 dosage:.After 21 days, observe mouse survival quantity, calculate survival rate.Result shows, and fibroblast growth factor suppresses polypeptide effectively can protect small white mouse, improves the survival rate of tumor-bearing mice, 0.75,1.5,3mg/Kg survival rate reaches 98.12%, 91.23%, 88.4%, corresponding taxol 42.2%.
Embodiment 4 suppresses the ELISA kit of polypeptide to detect containing fibroblast growth factor: enzyme connects immunoadsorption assay (ELISA) test kit and comprises following reagent:
(1) coating buffer: 0.05mol/L carbonate buffer solution (pH9.6).Take 0.75g sodium carbonate, 1.46g sodium bicarbonate, add deionized water and be settled to 500ml;
(2) PBS damping fluid: 0.02mol/L phosphate buffered saline buffer (pH7.4).Take 0.2g potassium primary phosphate, 2.90g Sodium phosphate dibasic, 8g sodium-chlor, add deionized water constant volume to 1000ml;
(3) antibody diluent: 0.02mol/LPBS (pH7.4) and 0.2%BSA.Take 0.2gBSA to add the 0.02mol/L phosphate buffered saline buffer for preparing and dissolve quantitatively to 100ml;
(4) confining liquid: 0.05mol/L carbonate buffer solution (pH9.6) and 2.0%BSA.2.0gBSA adds the 0.05mol/L carbonate buffer solution prepared and dissolves quantitatively to 100ml;
(5) washings: 0.02mol/LPBS (pH7.4) and 0.05%Tween-20.50ulTween-20 is dissolved in 100ml0.02mol/L phosphate buffered saline buffer, concussion mixing;
(6) substrate solution: solubility single-component tmb substrate solution;
(7) stop buffer: 2mol/L sulphuric acid soln.The 10ml98% vitriol oil adds in 60ml distilled water, is settled to 100ml, room temperature preservation;
(8) fibroblast growth factor suppresses polypeptide
(9) fibroblast growth factor antibody grinds bio tech ltd purchased from Shanghai one
(10) two anti-(goat anti-mouse IgG) are purchased from the prompt Science and Technology Ltd. of Amy
Using method: 1, serum sample preparation: get 3 tumor bearing nude mices, carry out eye socket and get blood, every only 200 μ L, Quick spin 12000rpm 3min, get supernatant, 1:2 adds PBS by volume, 80 DEG C of water-bath 30min, 12000rpm 3min gets supernatant, and-20 DEG C frozen for subsequent use.2, fibroblast growth factor antibody is coated antibody, and fibroblast growth factor antibody is dissolved in bag by diluent, concentration is 100 μ g/mL.The 96 every holes of hole enzyme plate add 100 μ L, and 4 DEG C of bags are spent the night.Discard coating buffer, add confining liquid 200 μ L, 37 DEG C of closed 1h.Discard confining liquid, serum sample 100 μ L (thinning ratio 1:50) and the fibroblast growth factor that add sample diluting liquid dilution respectively suppress polypeptide 100 μ L (10 μ g/ml) and above-mentioned serum sample 50 μ L and fibroblast growth factor to suppress the mixture of polypeptide 50 μ L, be divided into 3 groups, hatch 1h for 37 DEG C.Discard serum, PBST and tap water interval wash three times.After washing, every hole adds sample diluting liquid dilution ELIAS secondary antibody 100 μ L (thinning ratio 1:10000), hatches 1h for 37 DEG C.Discard two to resist, washing.After washing, every hole adds 100 μ L substrate solutions (50 μ L substrate A, 50 μ L substrate B), after 37 DEG C of reaction 30min, adds 50 μ L 2M H
2sO
4termination reaction, measures the optical density value OD in every hole at 450nm wavelength by microplate reader
450nm.
Result: fibroblast growth factor suppress polypeptide can with fibroblast growth factor antibodies, and fibroblast growth factor in serum can be competed, therefore be illustrated as fibroblast growth factor and suppress polypeptide competition law to detect Notch, realize tumour prediction;
SEQUENCE LISTING
Pu Luoda bio tech ltd, <110> Suzhou
<120> fibroblast growth factor suppresses polypeptide and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 26
<212> PRT
<213> artificial sequence
<400> 1
Gly Met Leu Gly Gly Gln Glu Met Trp Ser Trp Lys Cys Leu Leu Phe
1 5 10 15
Trp Leu Lys Arg Arg Asn Phe Trp Gln Gly
20 25
Claims (5)
1. fibroblast growth factor suppresses polypeptide, it is characterized in that its sequence is GMLGGQEMWSWKCLLFWLKRRNFWQG.
2. fibroblast growth factor as claimed in claim 1 suppresses the application of polypeptide in preparation tumor.
3. fibroblast growth factor as claimed in claim 1 suppresses polypeptide preparing the application in Hepatoma therapy medicine.
4. detect a test kit for tumour, it contains fibroblast growth factor according to claim 1 and suppresses polypeptide.
5. test kit as claimed in claim 4, is characterized in that also having
(1) the 0.05mol/L carbonate buffer solution of coating buffer: pH9.6;
(2) the 0.02mol/L phosphate buffered saline buffer of PBS damping fluid: pH7.4;
(3) 0.02mol/LPBS and 0.2%BSA of antibody diluent: pH7.4;
(4) the 0.05mol/L carbonate buffer solution of confining liquid: pH9.6 and 2.0%BSA
(5) washings: 0.02mol/LPBS (pH7.4) and 0.05%Tween-20;
(6) substrate solution: solubility single-component tmb substrate solution;
(7) stop buffer: 2mol/L sulphuric acid soln;
(8) fibroblast growth factor antibody;
(9) goat anti-mouse IgG.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510149467.7A CN104693288A (en) | 2015-03-31 | 2015-03-31 | Fibroblast growth factor inhibiting polypeptides and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510149467.7A CN104693288A (en) | 2015-03-31 | 2015-03-31 | Fibroblast growth factor inhibiting polypeptides and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104693288A true CN104693288A (en) | 2015-06-10 |
Family
ID=53340875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510149467.7A Withdrawn CN104693288A (en) | 2015-03-31 | 2015-03-31 | Fibroblast growth factor inhibiting polypeptides and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104693288A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1414020A (en) * | 2002-07-12 | 2003-04-30 | 人体基因组科学有限公司 | Desmocyte growth factor 11 antibody, antagonist and agonist |
| CN1634028A (en) * | 2004-11-11 | 2005-07-06 | 中山大学 | Use of ampelopsin in preparation of angiogenesis inhibitor drug |
-
2015
- 2015-03-31 CN CN201510149467.7A patent/CN104693288A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1414020A (en) * | 2002-07-12 | 2003-04-30 | 人体基因组科学有限公司 | Desmocyte growth factor 11 antibody, antagonist and agonist |
| CN1634028A (en) * | 2004-11-11 | 2005-07-06 | 中山大学 | Use of ampelopsin in preparation of angiogenesis inhibitor drug |
Non-Patent Citations (1)
| Title |
|---|
| 冷吉燕等: "20（s）-原人参二醇对肝癌血管内皮生长因子及碱性成纤维细胞生长因子蛋白表达的影响", 《临床肝胆病杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keliher et al. | Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection | |
| CN103558170B (en) | Folic acid-platinum-graphene oxide composite nano material and detection tumour cell thereof | |
| Wang et al. | Tumor vessel targeted self-assemble nanoparticles for amplification and prediction of the embolization effect in hepatocellular carcinoma | |
| CN108404138A (en) | A kind of conjugate and its application of targeting CD24 monoclonal antibodies and two alkoxide of diethylamine azo | |
| Wang et al. | Upconversion nanoprobes for in vitro and ex vivo measurement of carbon monoxide | |
| CN104672313A (en) | Jaggedl agonist polypeptide and application thereof | |
| CN103145803B (en) | Polypeptide in specific binding with breast cancer brain metastases cells | |
| CN103450342B (en) | Tetrahydroisoquinoline-3-carboxylic acid modify PARGD seven peptide, its synthesis, antithrombotic acitivity and application | |
| Luo et al. | Self-anti-angiogenesis nanoparticles enhance anti-metastatic-tumor efficacy of chemotherapeutics | |
| CN104725486A (en) | Fibroblast growth factor inhibiting polypeptide and application thereof | |
| CN103328496A (en) | Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis | |
| Liu et al. | A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling | |
| CN104262373B (en) | A kind of targeting detection the fluorescence probe of inhibition cancer cell, preparation method and application | |
| CN104693288A (en) | Fibroblast growth factor inhibiting polypeptides and application thereof | |
| CN106029683A (en) | Polypeptide and polypeptide complex for suppressing tumor metastasis and treating leukemia as well as preparation method therefor and application thereof | |
| CN104693287A (en) | Fibroblast growth factor inhibitory polypeptide and application thereof | |
| CN103450344B (en) | Tetrahydroisoquinoline-3-carboxylic acid modify LARGD seven peptide, its synthesis, antithrombotic acitivity and application | |
| CN104710513A (en) | Melanoma cell adhesion molecule antagonist polypeptide and application thereof | |
| CN106699850A (en) | RBBP4 targeting polypeptide and anti-tumor polypeptide, and applications thereof | |
| CN104710514A (en) | Vascular endothelial cadherin antagonist polypeptide and application thereof | |
| CN108030777B (en) | Chloroguanide application in preparation of anti-tumor drugs | |
| CN103450343B (en) | Tetrahydroisoquinoline-3-carboxylic acid modify TARGD seven peptide, its synthesis, antithrombotic acitivity and application | |
| CN104761622A (en) | Jaggedl-associated agonist polypeptide and application thereof | |
| CN104693278A (en) | Jagged1 agonist polypeptide and application thereof | |
| CN104725483A (en) | Melanoma cell adhesion molecule antagonist polypeptide and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150610 |
|
| WW01 | Invention patent application withdrawn after publication |